Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full
Read more
– Total revenue increased 51 percent to $137.1 million – – Epidiolex for seizures associated with TSC launched in the U.S. –– Nabiximols Phase 3 program in MS spasticity now recruiting –– Conference call today
Read more
GW’s cannabis-based medicine rescheduled following approval by the European Medicines Agency (EMA) and an independent assessment by the Advisory Council
Read more
DUBLIN, June 17, 2020 /PRNewswire/ — Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today
Read more
TORONTO–(BUSINESS WIRE)–FSD Pharma Inc. (Nasdaq: HUGE) (CSE: HUGE.CN) (FRA: 0K9A) (“FSD Pharma” or the “Company”) today reported that management’s discussion and analysis
Read more